Literature DB >> 15271853

STK15 polymorphism and breast cancer risk in a population-based study.

Kathleen M Egan1, Polly A Newcomb, Christine B Ambrosone, Amy Trentham-Dietz, Linda Titus-Ernstoff, John M Hampton, Makoto T Kimura, Hiroki Nagase.   

Abstract

STK15 is considered a potential cancer susceptibility gene owing to its functions in normal cell mitosis. Two common coding region polymorphisms in the gene (F31I and V57I) may affect ubiquitin-dependent degradation and thus the half-life of the encoded protein. There are limited data on the relevance of these polymorphisms to population cancer rates. To examine whether functional variation in STK15 may affect breast cancer risk, we genotyped a large series of incident breast cancer cases (n = 941) and age-matched population controls (n = 830) for the F31I and V57I polymorphisms. Individually, neither the F31I polymorphism [odds ratio (OR) 1.54; 95% confidence interval (CI) 0.96-2.47, comparing 31I with 31F homozygotes] nor the V57I polymorphism (OR 0.92; 95% CI 0.50-1.71, comparing 57I with 57V homozygotes) was significantly associated with breast cancer risk. A relatively common genotype, combining the two polymorphisms (31I-57V/31I-57V, 3% of controls) was related to a significant 2-fold increase in the risk of post-menopausal breast cancer (OR 1.96; 95% CI 1.01-3.79). No interaction was detected between STK15 variants and estrogenic risk factors, although the power of these analyses was limited. These results suggest that STK15 may represent a low penetrance type breast cancer susceptibility gene.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271853     DOI: 10.1093/carcin/bgh231

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  13 in total

1.  Association between the STK15 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Jun Qin; Xiao-Feng He; Wu Wei; Zhi-Zhong Liu; Jian-Jun Xie; Wei Wang; Ya-Ping Du; Yu Chen; Hui-Qiang Si
Journal:  Mol Genet Genomics       Date:  2014-08-26       Impact factor: 3.291

2.  A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).

Authors:  Yael P Mossé; Elizabeth Fox; David T Teachey; Joel M Reid; Stephanie L Safgren; Hernan Carol; Richard B Lock; Peter J Houghton; Malcolm A Smith; David Hall; Donald A Barkauskas; Mark Krailo; Stephan D Voss; Stacey L Berg; Susan M Blaney; Brenda J Weigel
Journal:  Clin Cancer Res       Date:  2019-02-18       Impact factor: 12.531

3.  Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk.

Authors:  Makoto T Kimura; Takahiro Mori; Jeffrey Conroy; Norma J Nowak; Susumu Satomi; Katsuyuki Tamai; Hiroki Nagase
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

4.  Genetic variation in cell cycle regulatory gene AURKA and association with intrinsic breast cancer subtype.

Authors:  Nicholas J Taylor; Jeannette T Bensen; Charles Poole; Melissa A Troester; Marilie D Gammon; Jingchun Luo; Robert C Millikan; Andrew F Olshan
Journal:  Mol Carcinog       Date:  2014-10-18       Impact factor: 4.784

5.  Breast Cancer Risk Associated with Genotype Polymorphisms of the Aurora Kinase a Gene (AURKA): a Case-Control Study in a High Altitude Ecuadorian Mestizo Population.

Authors:  Andrés López-Cortés; Alejandro Cabrera-Andrade; Fabián Oña-Cisneros; Carolina Echeverría; Felipe Rosales; Malena Ortiz; Eduardo Tejera; César Paz-Y-Miño
Journal:  Pathol Oncol Res       Date:  2017-06-24       Impact factor: 3.201

6.  AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.

Authors:  Fergus J Couch; Olga Sinilnikova; Robert A Vierkant; V Shane Pankratz; Zachary S Fredericksen; Dominique Stoppa-Lyonnet; Isabelle Coupier; David Hughes; Agnès Hardouin; Pascaline Berthet; Susan Peock; Margaret Cook; Caroline Baynes; Shirley Hodgson; Patrick J Morrison; Mary E Porteous; Anna Jakubowska; Jan Lubinski; Jacek Gronwald; Amanda B Spurdle; Rita Schmutzler; Beatrix Versmold; Christoph Engel; Alfons Meindl; Christian Sutter; Jurgen Horst; Dieter Schaefer; Kenneth Offit; Tomas Kirchhoff; Irene L Andrulis; Eduard Ilyushik; Gordon Glendon; Peter Devilee; Maaike P G Vreeswijk; Hans F A Vasen; Ake Borg; Katja Backenhorn; Jeffery P Struewing; Mark H Greene; Susan L Neuhausen; Timothy R Rebbeck; Katherine Nathanson; Susan Domchek; Theresa Wagner; Judy E Garber; Csilla Szabo; Michal Zikan; Lenka Foretova; Janet E Olson; Thomas A Sellers; Noralane Lindor; Heli Nevanlinna; Johanna Tommiska; Kristiina Aittomaki; Ute Hamann; Muhammad U Rashid; Diana Torres; Jacques Simard; Francine Durocher; Frederic Guenard; Henry T Lynch; Claudine Isaacs; Jeffrey Weitzel; Olufunmilayo I Olopade; Steven Narod; Mary B Daly; Andrew K Godwin; Gail Tomlinson; Douglas F Easton; Georgia Chenevix-Trench; Antonis C Antoniou
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-07       Impact factor: 4.254

7.  Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians.

Authors:  Jinyun Chen; Donghui Li; Chongjuan Wei; Subrata Sen; Ann M Killary; Christopher I Amos; Douglas B Evans; James L Abbruzzese; Marsha L Frazier
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

8.  Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Authors:  John M Maris; Christopher L Morton; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

9.  Association between the STK15 F31I polymorphism and cancer susceptibility: a meta-analysis involving 43,626 subjects.

Authors:  Weifeng Tang; Hao Qiu; Hao Ding; Bin Sun; Lixin Wang; Jun Yin; Haiyong Gu
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

10.  Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC).

Authors:  Eiji Ogawa; Kazumasa Takenaka; Hiromichi Katakura; Masashi Adachi; Yosuke Otake; Yoshinobu Toda; Hirokazu Kotani; Toshiaki Manabe; Hiromi Wada; Fumihiro Tanaka
Journal:  Ann Surg Oncol       Date:  2007-11-28       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.